Position of the Transparency Council – Quviviq (daridorexant)
At its meeting on 23 December 2024, the Transparency Council adopted position No. 155/2024 on the appropriateness of issuing approvals for reimbursement of the drug Quviviq (daridorexant) for the indication: inorganic insomnia